Effect of FK506 on insulin secretion in normal dogs

Sheryl Strasser, Rodolfo Alejandro, E. Timothy Shapiro, Camillo Ricordi, S. Todo, Daniel H. Mintz

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

In this report, we describe the effect of FK506 on glucose-mediated insulin release in normal dogs. Dogs were placed into one of two groups, group 1 dogs received FK506 (1 mg/kg/d orally) for 2 weeks, and group 2 dogs received FK506 at the same dose, but for 4 weeks. Following the treatment period, both groups of dogs were allowed a recovery period during which time no FK506 was administered. Intravenous glucose tolerance tests (IVGTT) were performed (0.5 mg/kg IV) before FK506 treatment, after 2 or 4 weeks of treatment, and following the recovery periods. Complete blood cell counts (CBC) and serum chemistries were also obtained at these times. Following FK506 treatment for either 2 or 4 weeks, the dogs experienced a delay in glucose disappearance in response to IV glucose injection. Insulin secretion during IVGTT was unchanged in dogs treated for only 2 weeks, but was significantly decreased in dogs treated for 4 weeks. Following the recovery period, glucose disappearance during IVGTT returned to normal in dogs that were treated for 2 weeks, and was more rapid than normal in dogs that had been treated for 4 weeks. Insulin secretion after the recovery period remained unchanged in group 1 dogs, but continued to be significantly reduced in group 2 dogs that had received FK506 for 4 weeks. No significant change was detected in the CBCs or serum chemistries.

Original languageEnglish
Pages (from-to)64-67
Number of pages4
JournalMetabolism
Volume41
Issue number1
DOIs
StatePublished - Jan 1 1992

Fingerprint

Tacrolimus
Dogs
Insulin
Glucose Tolerance Test
Glucose
Blood Cell Count
Therapeutics
Serum

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effect of FK506 on insulin secretion in normal dogs. / Strasser, Sheryl; Alejandro, Rodolfo; Shapiro, E. Timothy; Ricordi, Camillo; Todo, S.; Mintz, Daniel H.

In: Metabolism, Vol. 41, No. 1, 01.01.1992, p. 64-67.

Research output: Contribution to journalArticle

Strasser, Sheryl ; Alejandro, Rodolfo ; Shapiro, E. Timothy ; Ricordi, Camillo ; Todo, S. ; Mintz, Daniel H. / Effect of FK506 on insulin secretion in normal dogs. In: Metabolism. 1992 ; Vol. 41, No. 1. pp. 64-67.
@article{ab9abbb51c634f67b3307e3950689670,
title = "Effect of FK506 on insulin secretion in normal dogs",
abstract = "In this report, we describe the effect of FK506 on glucose-mediated insulin release in normal dogs. Dogs were placed into one of two groups, group 1 dogs received FK506 (1 mg/kg/d orally) for 2 weeks, and group 2 dogs received FK506 at the same dose, but for 4 weeks. Following the treatment period, both groups of dogs were allowed a recovery period during which time no FK506 was administered. Intravenous glucose tolerance tests (IVGTT) were performed (0.5 mg/kg IV) before FK506 treatment, after 2 or 4 weeks of treatment, and following the recovery periods. Complete blood cell counts (CBC) and serum chemistries were also obtained at these times. Following FK506 treatment for either 2 or 4 weeks, the dogs experienced a delay in glucose disappearance in response to IV glucose injection. Insulin secretion during IVGTT was unchanged in dogs treated for only 2 weeks, but was significantly decreased in dogs treated for 4 weeks. Following the recovery period, glucose disappearance during IVGTT returned to normal in dogs that were treated for 2 weeks, and was more rapid than normal in dogs that had been treated for 4 weeks. Insulin secretion after the recovery period remained unchanged in group 1 dogs, but continued to be significantly reduced in group 2 dogs that had received FK506 for 4 weeks. No significant change was detected in the CBCs or serum chemistries.",
author = "Sheryl Strasser and Rodolfo Alejandro and Shapiro, {E. Timothy} and Camillo Ricordi and S. Todo and Mintz, {Daniel H.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1016/0026-0495(92)90192-D",
language = "English",
volume = "41",
pages = "64--67",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Effect of FK506 on insulin secretion in normal dogs

AU - Strasser, Sheryl

AU - Alejandro, Rodolfo

AU - Shapiro, E. Timothy

AU - Ricordi, Camillo

AU - Todo, S.

AU - Mintz, Daniel H.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - In this report, we describe the effect of FK506 on glucose-mediated insulin release in normal dogs. Dogs were placed into one of two groups, group 1 dogs received FK506 (1 mg/kg/d orally) for 2 weeks, and group 2 dogs received FK506 at the same dose, but for 4 weeks. Following the treatment period, both groups of dogs were allowed a recovery period during which time no FK506 was administered. Intravenous glucose tolerance tests (IVGTT) were performed (0.5 mg/kg IV) before FK506 treatment, after 2 or 4 weeks of treatment, and following the recovery periods. Complete blood cell counts (CBC) and serum chemistries were also obtained at these times. Following FK506 treatment for either 2 or 4 weeks, the dogs experienced a delay in glucose disappearance in response to IV glucose injection. Insulin secretion during IVGTT was unchanged in dogs treated for only 2 weeks, but was significantly decreased in dogs treated for 4 weeks. Following the recovery period, glucose disappearance during IVGTT returned to normal in dogs that were treated for 2 weeks, and was more rapid than normal in dogs that had been treated for 4 weeks. Insulin secretion after the recovery period remained unchanged in group 1 dogs, but continued to be significantly reduced in group 2 dogs that had received FK506 for 4 weeks. No significant change was detected in the CBCs or serum chemistries.

AB - In this report, we describe the effect of FK506 on glucose-mediated insulin release in normal dogs. Dogs were placed into one of two groups, group 1 dogs received FK506 (1 mg/kg/d orally) for 2 weeks, and group 2 dogs received FK506 at the same dose, but for 4 weeks. Following the treatment period, both groups of dogs were allowed a recovery period during which time no FK506 was administered. Intravenous glucose tolerance tests (IVGTT) were performed (0.5 mg/kg IV) before FK506 treatment, after 2 or 4 weeks of treatment, and following the recovery periods. Complete blood cell counts (CBC) and serum chemistries were also obtained at these times. Following FK506 treatment for either 2 or 4 weeks, the dogs experienced a delay in glucose disappearance in response to IV glucose injection. Insulin secretion during IVGTT was unchanged in dogs treated for only 2 weeks, but was significantly decreased in dogs treated for 4 weeks. Following the recovery period, glucose disappearance during IVGTT returned to normal in dogs that were treated for 2 weeks, and was more rapid than normal in dogs that had been treated for 4 weeks. Insulin secretion after the recovery period remained unchanged in group 1 dogs, but continued to be significantly reduced in group 2 dogs that had received FK506 for 4 weeks. No significant change was detected in the CBCs or serum chemistries.

UR - http://www.scopus.com/inward/record.url?scp=0026503869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026503869&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(92)90192-D

DO - 10.1016/0026-0495(92)90192-D

M3 - Article

C2 - 1371575

AN - SCOPUS:0026503869

VL - 41

SP - 64

EP - 67

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 1

ER -